GLENMARK PHARMACEUTICALS LTD. - Glenmarks novel molecule 'GRC 27864' for chronic inflammatory diseases including pain entering human trials

Download	< Back
03 Apr 2014
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated April 03, 2014 titled "Glenmarks novel molecule GRC 27864 for chronic inflammatory diseases including pain entering human trials".
View all announcements for GLENMARK PHARMACEUTICALS LTD.	Source: BSE India

ALL MONEYWIZ PAGES

Stocks	Mutual Funds		Investment tracking
A-Z Gainers - Daily \| Weekly \| Monthly Losers - Daily \| Weekly \| Monthly Group-wise listing IPO \| Top IPOs Recent IPOs \| IPO News Similar Price band Most traded - By volumes Top 100 - By market capitalisation Latest Company Results Management Speaks Market News	Top 25 schemes High-risk, High-returns Medium-risk, Medium-returns Low-risk, Low-returns Gilt Funds Funds of Funds Special Funds Liquid Funds Dynamic Asset Allocation NFOs MF Selector	Equity - ELSS Equity - Index Funds Equity - Sector Funds Equity - Balance Fund Equity - Diversified Fund MF News Budget 2024	My Portfolio My Watch List If You Had Invested... Global Indicators Forex Converter Market Indices Sectoral Indices World Indices Market Astrology Advertise with us